Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 18, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Dabigatran Etexilate Capsules, 75 mg and 150 mg and Tentative approval for Dabigatran Etexilate Capsules, 110 mg".